Pharmacovigilance in the Real World

In this issue, Fralick and colleagues use real-world observational data to clarify discrepant findings from clinical trials on whether canagliflozin, a sodium–glucose cotransporter-2 inhibitor, increases risk for fracture. The editorialists discuss the findings and why they believe that real-world data are critical to pharmacovigilance.

http://bit.ly/2EZLCEL